Date of Report (Date of earliest event reported) | March 10, 2020 |
AquaBounty Technologies, Inc. |
(Exact name of registrant as specified in its charter) |
Delaware | 001-36426 | 04-3156167 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
2 Mill & Main Place, Suite 395, Maynard, Massachusetts | 01754 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code | 978-648-6000 |
(Former name or former address, if changed since last report.) |
Title of each class | Trading Symbol(s) | Name of exchange on which registered |
Common Stock, par value $0.001 per share | AQB | The NASDAQ Stock Market LLC |
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
AquaBounty Technologies, Inc. | ||
(Registrant) | ||
March 10, 2020 | /s/ David A. Frank | |
David A. Frank | ||
Chief Financial Officer |
• | Sylvia Wulf assumed the position of Chief Executive Officer, President, and Director; |
• | The U.S. Food and Drug Administration (“FDA”) lifted its Import Alert, allowing the Company to import its AquAdvantage eggs from its hatchery in Canada to its farm in Indiana; |
• | The Company’s Rollo Bay farm site received two regulatory approvals: FDA approved the farm’s hatchery building, and Environment and Climate Change Canada approved the farm’s production facility for the commercial grow-out of AquAdvantage Salmon; |
• | The Company’s Indiana farm received two batches of AquAdvantage eggs and is now producing both conventional and AquAdvantage Salmon, bringing total biomass at the farm to 160 tons at year end; |
• | Closed the Panama demonstration farm; |
• | Received approval in China to conduct a field trial for AquAdvantage Salmon; and |
• | Commenced marketing and communications activities, including qualitative and quantitative consumer research in preparation for commercialization. |
• | Completed two public offerings of common shares, raising net funds of $12.4 million; |
• | The Company’s Canadian subsidiary received two construction loan instalments totalling $900 thousand from the Department of Economic Development of the Province of Prince Edward Island and the Atlantic Canada Opportunities Agency; and |
• | Net loss for the year increased to $13.2 million (2018: $10.4 million) with the ramp-up of production operations in Indiana and Rollo Bay, increased legal fees in support of the FDA legal challenge, and increased headcount. |
As of | |||||||
December 31, | |||||||
2019 | 2018 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 2,798,744 | $ | 3,002,557 | |||
Other receivables | 55,198 | 115,982 | |||||
Inventory | 1,232,049 | 76,109 | |||||
Prepaid expenses and other current assets | 391,162 | 315,969 | |||||
Total current assets | 4,477,153 | 3,510,617 | |||||
Property, plant and equipment, net | 25,065,836 | 23,716,768 | |||||
Right of use assets, net | 399,477 | — | |||||
Definite-lived intangible assets, net | 157,588 | 171,292 | |||||
Indefinite-lived intangible assets | 101,661 | 191,800 | |||||
Other assets | 32,024 | 80,583 | |||||
Total assets | $ | 30,233,739 | $ | 27,671,060 | |||
Liabilities and stockholders’ equity | |||||||
Current liabilities: | |||||||
Accounts payable and accrued liabilities | $ | 1,462,809 | $ | 824,900 | |||
Other current liabilities | 62,286 | 20,423 | |||||
Current debt | 163,155 | 71,613 | |||||
Total current liabilities | 1,688,250 | 916,936 | |||||
Long-term lease obligations | 352,808 | — | |||||
Long-term debt | 4,432,052 | 3,519,821 | |||||
Total liabilities | 6,473,110 | 4,436,757 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity: | |||||||
Common stock, $0.001 par value, 50,000,000 shares authorized; | |||||||
21,635,365, (2018: 15,098,837) shares outstanding | 21,635 | 15,099 | |||||
Additional paid-in capital | 156,241,363 | 142,707,957 | |||||
Accumulated other comprehensive loss | (360,160 | ) | (574,186 | ) | |||
Accumulated deficit | (132,142,209 | ) | (118,914,567 | ) | |||
Total stockholders’ equity | 23,760,629 | 23,234,303 | |||||
Total liabilities and stockholders’ equity | $ | 30,233,739 | $ | 27,671,060 |
Years ended December 31, | |||||||||||
2019 | 2018 | 2017 | |||||||||
Revenues | |||||||||||
Product Revenues | $ | 186,738 | $ | 84,518 | $ | 53,278 | |||||
Costs and expenses | |||||||||||
Production costs | 3,573,858 | 2,626,353 | 1,193,566 | ||||||||
Sales and marketing | 709,023 | 297,687 | 799,009 | ||||||||
Research and development | 2,359,441 | 3,458,564 | 3,371,767 | ||||||||
General and administrative | 6,723,060 | 4,067,710 | 3,921,035 | ||||||||
Total costs and expenses | 13,365,382 | 10,450,314 | 9,285,377 | ||||||||
Operating loss | (13,178,644 | ) | (10,365,796 | ) | (9,232,099 | ) | |||||
Other income (expense) | |||||||||||
Interest expense | (62,988 | ) | (22,257 | ) | (21,537 | ) | |||||
Other income (expense), net | 13,990 | 5,994 | (5,011 | ) | |||||||
Total other income (expense) | (48,998 | ) | (16,263 | ) | (26,548 | ) | |||||
Net loss | $ | (13,227,642 | ) | $ | (10,382,059 | ) | $ | (9,258,647 | ) | ||
Other comprehensive income (loss): | |||||||||||
Foreign currency translation gain (loss) | 214,026 | (360,302 | ) | 72,388 | |||||||
Total other comprehensive income (loss) | 214,026 | (360,302 | ) | 72,388 | |||||||
Comprehensive loss | $ | (13,013,616 | ) | $ | (10,742,361 | ) | $ | (9,186,259 | ) | ||
Earnings per share | |||||||||||
Net loss | $ | (13,227,642 | ) | $ | (10,382,059 | ) | $ | (9,258,647 | ) | ||
Deemed dividend | $ | — | $ | (1,822,873 | ) | $ | — | ||||
Net loss attributable to common shareholders | $ | (13,227,642 | ) | $ | (12,204,932 | ) | $ | (9,258,647 | ) | ||
Basic and diluted net loss per share attributable to common shareholders | $ | (0.66 | ) | $ | (0.94 | ) | $ | (1.06 | ) | ||
Weighted average number of common shares -basic and diluted | 20,078,017 | 13,028,760 | 8,772,494 |
Years ended December 31, | |||||||||||
2019 | 2018 | 2017 | |||||||||
Operating activities | |||||||||||
Net loss | $ | (13,227,642 | ) | $ | (10,382,059 | ) | $ | (9,258,647 | ) | ||
Adjustment to reconcile net loss to net cash used in | |||||||||||
operating activities: | |||||||||||
Depreciation and amortization | 1,285,902 | 843,387 | 184,946 | ||||||||
Share-based compensation | 872,177 | 263,396 | 122,134 | ||||||||
Gain on disposal of equipment | (12,133 | ) | (13,233 | ) | (941 | ) | |||||
Loss on asset held for sale | 149,800 | — | — | ||||||||
Impairment loss | 103,116 | — | — | ||||||||
Other non-cash charges | — | (1,364 | ) | — | |||||||
Changes in operating assets and liabilities: | |||||||||||
Other receivables | 65,002 | 56,212 | (11,440 | ) | |||||||
Inventory | (1,154,222 | ) | 93,956 | (169,991 | ) | ||||||
Prepaid expenses and other assets | 59,942 | 289,868 | (592,602 | ) | |||||||
Accounts payable, accrued liabilities and other liabilities | 609,311 | (966,928 | ) | 625,763 | |||||||
Net cash used in operating activities | (11,248,747 | ) | (9,816,765 | ) | (9,100,778 | ) | |||||
Investing activities | |||||||||||
Purchase of property, plant and equipment | (2,316,809 | ) | (4,009,736 | ) | (18,893,264 | ) | |||||
Deposits on equipment purchases | (160,675 | ) | (95,001 | ) | (153,663 | ) | |||||
Proceeds from sale of equipment | 15,848 | 23,233 | 941 | ||||||||
Net cash used in investing activities | (2,461,636 | ) | (4,081,504 | ) | (19,045,986 | ) | |||||
Financing activities | |||||||||||
Proceeds from issuance of debt | 900,767 | 771,858 | 256,807 | ||||||||
Repayment of term debt | (85,802 | ) | (55,615 | ) | (35,812 | ) | |||||
Proceeds from the issuance of common stock and warrants, net | 12,395,348 | 10,616,046 | 24,989,257 | ||||||||
Proceeds from exercise of stock options and warrants, net | 272,417 | 5,116,533 | 27,502 | ||||||||
Net cash provided by financing activities | 13,482,730 | 16,448,822 | 25,237,754 | ||||||||
Effect of exchange rate changes on cash and cash equivalents | 23,840 | (54,279 | ) | 80,018 | |||||||
Net change in cash and cash equivalents | (203,813 | ) | 2,496,274 | (2,828,992 | ) | ||||||
Cash and cash equivalents at beginning of period | 3,002,557 | 506,283 | 3,335,275 | ||||||||
Cash and cash equivalents at the end of period | $ | 2,798,744 | $ | 3,002,557 | $ | 506,283 | |||||
Supplemental disclosure of cash flow information and non-cash transactions: | |||||||||||
Interest paid in cash | $ | 62,988 | $ | 22,257 | $ | 21,537 | |||||
Property and equipment included in accounts payable and accrued liabilities | $ | 210,270 | $ | 193,378 | $ | 1,036,240 | |||||
Acquisition of equipment under debt arrangement | $ | — | $ | 74,068 | — |